Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of once-daily umeclidinium versus placebo in adults with asthma
2016-002843-40Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in asthma (3 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in clinic trough FEV1 at Week 24. Started Jan 2017; status: completed.
02
Drugs
umeclidinium
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-002843-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002843-40.